After 'confusion' over Trump team's directives, critical NIH research will continue for now
Despite concerns about the future of research at the National Institutes of Health, current clinical trials can continue as scheduled, the agency's acting director told staff scientists in an email Monday.
The clarification followed what staffers called 'chaos' Wednesday when the Trump administration 'paused' all communications from federal health agencies and suspended all government travel. The directive left NIH staff members with unanswered questions about their work and even whether they'd be able to continue caring for their patients.
The acting director, Dr. Matthew Memoli, a longtime infectious disease expert and flu vaccine researcher at the NIH, wrote in the email, a copy of which was obtained by NBC News, that he sought to clear up 'confusion on the scope of the pause.'
'Clinical trials at NIH or NIH-funded institutions are ongoing,' he wrote. 'Research participants can continue to participate in clinical trials at the NIH Clinical Center and at NIH-funded facilities.'
He also clarified that investigators could continue to spend money on supplies and pay for research participants to travel to the NIH Clinical Center in Bethesda, Maryland, for treatment. The NIH conducts more than a thousand clinical trials every year.
A staff scientist who wasn't authorized to speak publicly said the email was 'good news' that seemed to 'put things back closer to normal,' as least for clinical work.
Funding for any new projects, however, remains on hold. It's unclear whether the NIH will continue approving money for research grants through its review groups, called study sections.
Without grants, scientists are unable to start any new research on conditions from asthma and pediatric cancer to Covid and Ebola. The NIH awards more than 60,000 grants every year, supporting at least 300,000 researchers.
Dr. Jay Bhattacharya, a Stanford University professor who publicly criticized how the NIH handled the Covid pandemic, has been tapped by President Donald Trump to be the next NIH director. A Senate hearing on whether to confirm Bhattacharya has not been scheduled.
Meantime, acting director Memoli said he expects additional guidance to come from the Department of Health and Human Services this week. The overall pause in external communications is expected to last until Saturday.
This article was originally published on NBCNews.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Senators grill NIH director in budget hearing: 4 takeaways
National Institutes of Health Director Jay Bhattacharya faced questions from senators during an Appropriations subcommittee hearing Tuesday, as the federal government agency has taken hits to its staffing levels and grant-making ability since under President Trump. Senators focused on the Trump administration's requested 2026 budget, which calls for cutting NIH's funding by $18 billion from 2025 levels. That roughly 40 percent reduction means 1,800 fewer new grants would be awarded and funded through the NIH and would impact many current grants, according to STAT. The budget also details Trump administration plans to restructure the agency and consolidate its 27 institutes into eight. Congress has the final say on how federal dollars are allocated, so the final NIH budget could look different. Here are four takeaways from the hearing: National Institutes of Health grant awards have plummeted since Trump returned to the White House in late January. One analysis found that the NIH has issued $2.3 billion less in new grant funds between January and April of this year than it did during that same time in 2024. Sen. Tammy Baldwin (D-Wis.) questioned Bhattacharya about the drop in grant funding and asked who was behind the decision to terminate or withhold funding. Bhattacharya, at first, tried to sidestep the question but eventually took responsibility for the agency's grant cancellations. 'There [have been] changes in priorities for the NIH, to move away from politicized science. I've made those decisions,' he said. 'Decisions regarding, for instance, Harvard and some other institutions, that's joint with the administration.' The NIH has canceled $9.5 billion worth of funding through 2,100 research grants since January and another $2.6 billion in contracts supporting clinical trials, according to a recent letter signed by more than 2,000 NIH scientists condemning the Trump administration's research cuts. Democratic Senators hammered Bhattacharya over the administration's desire to greatly reduce the NIH's spending. Sen. Dick Durbin (D-Ill) noted that research in his home state has taken a hit and that Northwestern University has not 'received a penny in NIH grants in 11 weeks.' 'I'm very hopeful that a resolution can be made with the universities where those decisions have been made,' Bhattacharya said. Sen. Susan Collins (R-Maine) questioned Bhattacharya over the NIH's decision to impose a 15 percent cap on indirect costs in grant research. Bhattacharya said that he could not speak directly to the cap since it is subject to litigation. Instead, he spoke to how changes in the NIH's grant funding process are an opportunity to ensure that funds are more broadly distributed across the country's research institutions. He argued that the agency's research funding 'very concentrated' with 20 universities receive 60 percent to 65 percent of NIH's funding. 'It's absolutely vital that the NIH's investments are geographically dispersed,' he said. 'I would love to work with Congress to think of ways to make NIH's investment in scientific research more geographically dispersed.' Sen. Patty Murray (D-Wash.) pushed Bhattacharya to answer long-standing questions about the consequences of the Trump administration's changes to the NIH, including just how many staff members have been terminated or left the agency amid threats of future layoffs. Murray also asked the director just how many clinical trials have been impacted by the NIH's grant terminations or pauses and how many fewer clinical trials the agency would be able to fund next year if the proposed budget were approved. Bhattacharya said he could not answer either question but pledged to send a response to Murray's office by the end of the day. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
The Hill
2 hours ago
- The Hill
Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul
Former White House COVID-19 response coordinator Ashish Jha, who served under President Biden, criticized the decision by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. to fire all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel. Kennedy announced the decision in an op-ed for The Wall Street Journal Monday, saying, 'A clean sweep is needed to re-establish public confidence in vaccine science.' But in an interview with CNN's Wolf Blitzer, Jha pushed back against Kennedy's reasoning. 'Look what he said in his op-ed was a series of nonsense about a group of individuals, experts…who shape what vaccines, if any, are going to be available to the American people,' Jha said in the interview. 'So obviously this is very concerning,' he continued. 'We'll have to see who he appoints next. But this is a step in the wrong direction.' Jha said he is concerned about what the move foretells about the secretary's agenda on vaccines. Jha pointed to what he characterized as a lackluster response from the secretary to 'the worst measles outbreak of the last 25 years.' He also expressed concern about Kennedy raising questions about vaccines causing autism, which Jha dismissed and said was 'settled science.' 'Then you put this in the middle of all of that,' Jha said, referring to the vaccine panel sweep, 'and what you have is a pretty clear picture that what Secretary Kennedy is trying to do is make sure that vaccines are not readily available to Americans, not just for kids, for the elderly.' 'He could go pretty far with this move, and I really am worried about where we're headed,' Jha continued. He said he's particularly concerned about the effect Kennedy's move will have on kids and whether they will continue having access to certain vaccines in the future. 'Kids rely on vaccines. I'm worried about whether the next generation of kids are going to have access to polio vaccines and measles vaccines. That's where we're heading. That's what we have to push back against.' Kennedy said in his op-ed that he was removing every member of the panel to give the Trump administration an opportunity to appoint its own members. Kennedy has long accused ACIP members of having conflicts of interest, sparking concern among vaccine advocates that he would seek to install members who are far more skeptical of approving new vaccines. But Jha pushed back against criticism that the panel was all Biden-appointed experts, saying, 'When the Biden administration came in, almost all of the appointees had come from the first Trump administration.' 'That was fine because they were good people,' he said. 'They were experts. Right now, it's the same thing. The people he is firing are experts — like a nurse in Illinois who spent her entire career getting kids vaccinated, cancer doctors from Memorial Sloan Kettering — like these are really good people.' 'And generally, CDC has not worried about when were they appointed. The question is, are they good and are they conflict free.'
The Hill
2 hours ago
- The Hill
Trump administration vs. mRNA vaccines
The Big Story President Trump once heralded the speedy development of an mRNA vaccine, but his new administration is casting doubts and fostering speculation over their use. © AP The Department of Health and Human Services (HHS) in late May canceled $766 million awarded to Moderna through the Biomedical Advanced Research and Development Authority (BARDA) to develop a potential mRNA vaccine for bird flu. This came soon after HHS Secretary Robert F. Kennedy Jr. announced COVID-19 mRNA vaccines would no longer be recommended for children and pregnant women, though the Centers for Disease Control and Prevention (CDC) kept the shot on its schedule of childhood vaccinations. The vaccines marked a breakthrough in medical technology, drastically reducing the timeline for development of targeted vaccines and even showing promise in cancer research. Trump called mRNA the 'gold standard' when he rolled out the first COVID-19 vaccines. In remarks in December 2020, the same month the first COVID-19 vaccines were deployed, Trump praised Operation Warp Speed's ability to develop a SARS-CoV-2 vaccine at a 'breakneck speed,' adding, 'the gold standard vaccine has been done in less than nine months.' According to Joseph Varon, president and chief medical officer of the Independent Medical Alliance, the concerns for mRNA vaccine skeptics are the expedited timeline and the conditions in which the COVID-19 vaccine was approved. 'The biggest concern is that this rushed treatment still remains in use, even under an Emergency Use Authorization in some cases. It needs to be sent back through proper studies and vetting,' Varon told The Hill. In a move that could prevent future mRNA vaccines from receiving approval, Kennedy on Tuesday announced he was removing every member of the independent panel advising the CDC on vaccines. In a Wall Street Journal op-ed, he wrote, 'A clean sweep is needed to re-establish public confidence in vaccine science.' Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel, Joseph Choi and Alejandra O'Connell-Domenech — every week we follow the latest moves on how Washington impacts your health. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the health care sector this week and beyond: Senators grill NIH director in budget hearing: 4 takeaways National Institutes of Health Director Jay Bhattacharya faced questions from senators during an Appropriations subcommittee hearing Tuesday, as the federal government agency has taken hits to its staffing levels and grant-making ability since under President Trump. Senators focused on the Trump administration's requested 2026 budget, which calls for cutting NIH's funding by $18 billion from 2025 levels. … States sue 23andMe over genetic data sales More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to auction off personal genetic information without their customers' knowledge or consent. 'The Pitt' actor Noah Wyle to make push for health care workers at Capitol Noah Wyle is heading to the pit of political power, with a visit to Capitol Hill to push for funding for programs aimed at improving mental health services for health care workers. 'The Pitt' and former 'ER' star will touch down in Washington on Thursday to lead a panel discussion at the Cannon House Office Building focused on the 'daily mental health, financial, and bureaucratic challenges for … In Other News Branch out with a different read: Collins calls Kennedy's firing of vaccine experts 'excessive' Sen. Susan Collins (R-Maine) on Monday called Health and Human Services Secretary Robert F. Kennedy Jr.'s firing of all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel 'excessive,' but she cautioned she needs to learn more about the decision. Kennedy announced the decision in an op-ed for The Wall Street Journal, catching many GOP lawmakers by surprise. 'I did not know that that had happened,' … Around the Nation Local and state headlines on health care: What We're Reading Health news we've flagged from other outlets: What Others are Reading Most read stories on The Hill right now: Judge declines to block Trump's Corporation for Public Broadcasting firings but allows board members to stay Correction: A previous version of this article gave incorrect names of the fired CPB board members. They are Laura Ross, Diane Kaplan and Thomas Rothman. … Read more Newsom asks judge for emergency intervention in Trump troop deployment in LA California Gov. Gavin Newsom (D) asked a federal judge to immediately intervene on Tuesday to limit President Trump's deployment of the National … Read more You're all caught up. See you tomorrow! Thank you for signing up! Subscribe to more newsletters here
